

Freedom of Information Request	FOI 23-359	11 August 2023
--------------------------------	------------	----------------

## Your request

You requested the following:

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
  - a) CAPOX (Capecitabine with Oxaliplatin)
  - b) FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
  - c) Lonsurf (Trifluridine - tipiracil)
  - d) Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - e) Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - f) Any other systemic anti-cancer therapy
  - g) Palliative care only
  
2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
  - a) Nivolumab monotherapy or combination with Ipilimumab
  - b) Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - c) Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - d) Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  - e) Any other systemic anti-cancer therapy
  - f) Palliative care only
  
3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:
  - a) Nivolumab monotherapy or combination with Ipilimumab
  - b) Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - c) Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - d) Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  - e) Any other systemic anti-cancer therapy
  - f) Palliative care only

4. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:
  - a) Nivolumab monotherapy or in combination with Ipilimumab
  - b) Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - c) Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.
6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

## **Our response**

1. We do not hold the information requested for points 1a-1f. You may wish to direct your request to Velindre University NHS Trust, which delivers Oesophageal and Gastric chemotherapy on behalf of the Health Board.

Our response for 1g is 3 patients.

2. We do not hold the information requested for points 2a-2e. You may wish to direct your request to Velindre University NHS Trust, which delivers Oesophageal and Gastric chemotherapy on behalf of the Health Board.

Our response for 2f is 4 patients.

3. We do not hold the information requested for points 3a-3e. You may wish to direct your request to Velindre University NHS Trust, which delivers Oesophageal and Gastric chemotherapy on behalf of the Health Board.

We are unable to provide the figures for 3f as data is only collected up to the First Definitive Treatment. If the patient has been resected as a first treatment, then we would not be able to identify from our database if they went on to have palliative care.

4. We do not hold the information requested. You may wish to direct your request to Velindre University NHS Trust, which delivers Oesophageal and Gastric chemotherapy on behalf of the Health Board.
5. We do not undertake any research trials specifically for gastric cancer.
6. We do not undertake any research trials specifically for oesophageal cancer.